Clinical trial · Observational
The Kinetics Profiling of Immune Reconstitution and Clinical Outcomes
Retrospective and Prospective Study on the Kinetics Profiling of Immune Reconstitution and Clinical Outcomes in CMML Following Allogeneic Hematopoietic Stem Cell Transplantation
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic malignancy with poor prognosis. Allogeneic hematopoietic stem cell transplantation (HSCT) remains the only potentially curative treatment. Immune reconstitution (IR) is critical for improving HSCT efficacy and quality of life among survivors, yet its dynamic impact on survival and complications like chronic graft-versus-host disease (cGVHD) in CMML is poorly defined. This study aimed to investigate the dynamics of IR following HSCT in patients with CMML and evaluate its impact on post-transplant clinical outcomes.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chronic Myelomonocytic Leukemia (CMML) | Chronic Myelomonocytic Leukemia | ALIAS | 0.90 |
| Immune Reconstitution | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| immune reconstitution | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Retrospective cohort
- description
- Patients whose first visit to our institution and the termination of follow-up both occurred before the opening of this study will contribute to the retrospective cohort.
- interventionNames
- Other: immune reconstitution
- label
- Prospective cohort
- description
- Patients whose first visit to our institution occur after the opening of this study will contribute to the prospective cohort.
- interventionNames
- Other: immune reconstitution
- label
- Retrospective/Prospective cohort
- description
- Patients whose first visit to our institution occurred before the opening of this study and whose follow-up will terminate after the opening of this study will contribute to the ambispective cohort.
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: 1. Patients with confirmed diagnosis of CMML following HSCT 2. Patients treated at Peking University People's Hospital since January 1, 2005 Exclusion Criteria: 1. Any condition that may render follow-up data unreliable, including but not limited to severe psychiatric disorders 2. Patients deemed ineligible for the study by investigators
References
Publications (0)
Data not yet available